Replies to post #7892 on Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

One positive note from that article was that the Comera exec admitted that the barriers to entry are high.

[halofan]

I recall at a recent conference (don't remember which one), Helen was asked about the Merck subcutaneous effort. My recollection is that she said she did not know what they were using, and then she went on, quite confidently, to explain why she was not particularly worried about the potential competition because HALO was so far advanced in subcu and has such a strong safety record, that future converters will want to go the least risky route (or something to that effect).